129 related articles for article (PubMed ID: 15870883)
1. Skeletal muscle wasting in tumor-bearing rats is associated with MyoD down-regulation.
Costelli P; Muscaritoli M; Bossola M; Moore-Carrasco R; Crepaldi S; Grieco G; Autelli R; Bonelli G; Pacelli F; Lopez-Soriano FJ; Argilés JM; Doglietto GB; Baccino FM; Rossi Fanelli F
Int J Oncol; 2005 Jun; 26(6):1663-8. PubMed ID: 15870883
[TBL] [Abstract][Full Text] [Related]
2. Muscle wasting in diabetic and in tumor-bearing rats: role of oxidative stress.
Mastrocola R; Reffo P; Penna F; Tomasinelli CE; Boccuzzi G; Baccino FM; Aragno M; Costelli P
Free Radic Biol Med; 2008 Feb; 44(4):584-93. PubMed ID: 18053817
[TBL] [Abstract][Full Text] [Related]
3. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia.
Guttridge DC; Mayo MW; Madrid LV; Wang CY; Baldwin AS
Science; 2000 Sep; 289(5488):2363-6. PubMed ID: 11009425
[TBL] [Abstract][Full Text] [Related]
4. NF-kappa B-mediated MyoD decay during muscle wasting requires nitric oxide synthase mRNA stabilization, HuR protein, and nitric oxide release.
Di Marco S; Mazroui R; Dallaire P; Chittur S; Tenenbaum SA; Radzioch D; Marette A; Gallouzi IE
Mol Cell Biol; 2005 Aug; 25(15):6533-45. PubMed ID: 16024790
[TBL] [Abstract][Full Text] [Related]
5. The AP-1/CJUN signaling cascade is involved in muscle differentiation: implications in muscle wasting during cancer cachexia.
Moore-Carrasco R; García-Martínez C; Busquets S; Ametller E; Barreiro E; López-Soriano FJ; Argilés JM
FEBS Lett; 2006 Jan; 580(2):691-6. PubMed ID: 16412434
[TBL] [Abstract][Full Text] [Related]
6. MEF2c-Dependent Downregulation of Myocilin Mediates Cancer-Induced Muscle Wasting and Associates with Cachexia in Patients with Cancer.
Judge SM; Deyhle MR; Neyroud D; Nosacka RL; D'Lugos AC; Cameron ME; Vohra RS; Smuder AJ; Roberts BM; Callaway CS; Underwood PW; Chrzanowski SM; Batra A; Murphy ME; Heaven JD; Walter GA; Trevino JG; Judge AR
Cancer Res; 2020 May; 80(9):1861-1874. PubMed ID: 32132110
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization.
Langen RC; Van Der Velden JL; Schols AM; Kelders MC; Wouters EF; Janssen-Heininger YM
FASEB J; 2004 Feb; 18(2):227-37. PubMed ID: 14769817
[TBL] [Abstract][Full Text] [Related]
8. The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia.
Moore-Carrasco R; Busquets S; Almendro V; Palanki M; López-Soriano FJ; Argilés JM
Int J Oncol; 2007 May; 30(5):1239-45. PubMed ID: 17390027
[TBL] [Abstract][Full Text] [Related]
9. Activation of Ca(2+)-dependent proteolysis in skeletal muscle and heart in cancer cachexia.
Costelli P; De Tullio R; Baccino FM; Melloni E
Br J Cancer; 2001 Apr; 84(7):946-50. PubMed ID: 11286475
[TBL] [Abstract][Full Text] [Related]
10. US researchers find key link in muscle-wasting syndrome.
Pirisi A
Lancet; 2000 Oct; 356(9237):1249. PubMed ID: 11072955
[No Abstract] [Full Text] [Related]
11. Modulations of the calcineurin/NF-AT pathway in skeletal muscle atrophy.
Costelli P; Almendro V; Figueras MT; Reffo P; Penna F; Aragno M; Mastrocola R; Boccuzzi G; Busquets S; Bonelli G; Lopez Soriano FJ; Argilés JM; Baccino FM
Biochim Biophys Acta; 2007 Jul; 1770(7):1028-36. PubMed ID: 17442496
[TBL] [Abstract][Full Text] [Related]
12. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products.
Acharyya S; Ladner KJ; Nelsen LL; Damrauer J; Reiser PJ; Swoap S; Guttridge DC
J Clin Invest; 2004 Aug; 114(3):370-8. PubMed ID: 15286803
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol does not ameliorate muscle wasting in different types of cancer cachexia models.
Busquets S; Fuster G; Ametller E; Olivan M; Figueras M; Costelli P; Carbó N; Argilés JM; López-Soriano FJ
Clin Nutr; 2007 Apr; 26(2):239-44. PubMed ID: 17261345
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of skeletal muscle depletion in wasting syndromes: role of ATP-ubiquitin-dependent proteolysis.
Costelli P; Baccino FM
Curr Opin Clin Nutr Metab Care; 2003 Jul; 6(4):407-12. PubMed ID: 12806214
[TBL] [Abstract][Full Text] [Related]
15. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting.
Busquets S; Figueras MT; Fuster G; Almendro V; Moore-Carrasco R; Ametller E; Argilés JM; López-Soriano FJ
Cancer Res; 2004 Sep; 64(18):6725-31. PubMed ID: 15374990
[TBL] [Abstract][Full Text] [Related]
16. Muscle myostatin signalling is enhanced in experimental cancer cachexia.
Costelli P; Muscaritoli M; Bonetto A; Penna F; Reffo P; Bossola M; Bonelli G; Doglietto GB; Baccino FM; Rossi Fanelli F
Eur J Clin Invest; 2008 Jul; 38(7):531-8. PubMed ID: 18578694
[TBL] [Abstract][Full Text] [Related]
17. The biological mechanisms of cancer-related skeletal muscle wasting: the role of progressive resistance exercise.
Al-Majid S; Waters H
Biol Res Nurs; 2008 Jul; 10(1):7-20. PubMed ID: 18705151
[TBL] [Abstract][Full Text] [Related]
18. Muscle wasting associated with cancer cachexia is linked to an important activation of the ATP-dependent ubiquitin-mediated proteolysis.
Llovera M; Garcia-Martinez C; Agell N; Lopez-Soriano FJ; Argiles JM
Int J Cancer; 1995 Mar; 61(1):138-41. PubMed ID: 7705927
[TBL] [Abstract][Full Text] [Related]
19. Anticytokine treatment prevents the increase in the activity of ATP-ubiquitin- and Ca(2+)-dependent proteolytic systems in the muscle of tumour-bearing rats.
Costelli P; Bossola M; Muscaritoli M; Grieco G; Bonelli G; Bellantone R; Doglietto GB; Baccino FM; Rossi Fanelli F
Cytokine; 2002 Jul; 19(1):1-5. PubMed ID: 12200106
[TBL] [Abstract][Full Text] [Related]
20. Selective up-regulation of tumor necrosis factor receptor I in tumor-bearing rats with cancer-related cachexia.
Catalano MG; Fortunati N; Arena K; Costelli P; Aragno M; Danni O; Boccuzzi G
Int J Oncol; 2003 Aug; 23(2):429-36. PubMed ID: 12851692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
